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Brachial versus basilic vein dialysis fistulas: A
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Objectives: Although the performance of basilic vein transpositions for dialysis access is well established, the utility and
patency rates of brachial vein transpositions are poorly characterized. The brachial vein is being used increasingly as an
alternative vein for transposition in an effort to increase the percentage of autogenous fistula utilization. The purpose of
this study was to review a single-center comparative experience with these fistulas.
Methods: A retrospective chart review was performed on 59 patients who received basilic and brachial vein transpositions
between January 2000 and December 2006. Patient demographics, comorbidities, mortality, and morbidity were
evaluated. Patency rates were calculated using Kaplan-Meier life-table analysis.
Results: Of 59 vein transpositions, there were 42 basilic (71%) and 17 brachial (29%). The 30-day mortality was 0%.
Maturation rates were 74% for basilic vein transpositions and 47% for brachial (P  .049). The mean time to maturation
was 11.9  8.8 weeks. Primary patency rates at 12 months were 50% for basilic vein transpositions vs 40% for brachial
(P  .115). The mean vein size was 4.9  0.9 mm. The mean basilic vein transposition diameter of 4.9  1.0 mm and
brachial vein transposition diameter of 5.0  0.8 mm were not significant (P  .39).
Conclusions: Despite a higher rate of initial maturation in basilic vein transpositions, brachial and basilic vein transposi-
tions had comparable patency rates at 12 months. These preliminary results require further follow-up and a larger cohort
of patients for confirmation. Broader use of the brachial vein transposition for dialysis appears justified and can increase
the overall percentage of autogenous fistula placement. ( J Vasc Surg 2008;47:402-6.)Dialysis access is a continual challenge for vascular sur-
geons and their patients. Maintaining adequate access usually
requires more than one procedure in life-long hemodialysis
patients. In 1966, Brescia and Cimino1 described the first
autogenous fistula. Which autogenous fistula is the best is the
subject of ongoing discussion and debate, and there is often
disagreement about which secondary and tertiary procedure is
the best after a failed initial fistula.
The United States has historically lagged behind Eu-
rope with respect to the prevalence of autogenous fistulas
used for dialysis, with a 24% vs 80% usage, respectively, in
the Dialysis Outcomes and Practice Patterns Study
(DOPPS).2 In 1997, the National Kidney Foundation–
Dialysis Quality Initiative (NKF-DOQI) proposed guide-
lines supporting increased usage of native veins for dialysis
access.3 These guidelines have since been revised, with
greater emphasis on strategies to increase autogenous fis-
tulas. As a result, surgeons have developed innovative tech-
niques and methods for improving autogenous access. In
fact, the drive for autogenous fistulas has led to a significant
increase in their usage to 46% nationwide in 2007.4
The basilic vein has long been viewed as an acceptable
conduit for an autogenous fistula. The basilic vein and brachial
artery anastomosis, performed by transposing the vein into a
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402subcutaneous tunnel, was first described for dialysis access by
Dagher et al5 in 1976. Many studies have since evaluated the
efficacy of the basilic vein for long-term dialysis access. 6-16
Proponents of the basilic vein transposition (BVT) maintain
that it is a suitable site for access because, like all autogenous
fistulas, it has a low incidence of infection, keeps the body free
from foreign material, and has longer patency rates than
polytetrafluoroethylene (PTFE).9,11 An additional advantage
is that the surgeon does not “burn any bridges” by attempting
a BVT; if it fails, then a subsequent ipsilateral graft can be
placed. The initial use of an upper extremity graft may pre-
clude the creation of a BVT afterwards.
The brachial vein, however, has rarely been studied as a
conduit for an autogenous fistula.16,17 Although it seems
intuitive that a brachial vein transposition (BrVT) would
possess the same advantages as a BVT, this technique may
have additional limitations. Concerns about vein diameter
and length available for mobilization, numerous branches,
and greater depth from the skin may discourage surgeons
from using this vein for a transposition. The purpose of this
study was to review a single institution’s short-term expe-
rience with BVT and BrVT.
MATERIALS AND METHODS
We used our institutional operative record/database to
identify 59 consecutive patients who underwent BVT or
BrVT at the Ochsner Clinic Foundation between January
2000 and December 2006. The study design and protocol
were approved by the Institutional Review Board. Retro-
spectively reviewed data were obtained from inpatient
charts, outpatient records, operating room notes, dialysis
records, and phone calls. Patient characteristics collected
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comorbidities. The preoperative vein diameter (as deter-
mined by vein mapping), number of prior access procedures,
and current hemodialysis status were also evaluated. The post-
operative rates for 30-day mortality, complications, matura-
tion, primary functional patency, and primary-assisted pa-
tency were studied. Maturation was defined as the time
until the primary fistula was suitable to allow successful
cannulation. Primary functional patency was defined as a
fistula that remained patent throughout follow-up and was
used for hemodialysis. Primary-assisted patency was defined
as maintained fistula flow as a result of an adjuvant proce-
dure or intervention.18
Patient selection. Patients were eligible for a transpo-
sition arteriovenous fistula if the veins were a minimum of
4.0 mm. When the basilic and brachial veins were compa-
rable in size, the basilic vein was selected. Primary radioce-
phalic or brachiocephalic fistulas were the first choice if a
cephalic vein 3.0 mm was present.
Surgical technique. Doppler studies have been
shown to be a reliable and effective evaluation of upper
extremity veins.19-22 At our institution, every patient re-
ceives preoperative vein mapping in our vascular lab. If no
suitable cephalic vein is identifiable for anastomosis with
the radial or brachial artery, the basilic and brachial veins are
evaluated. Either of these veins will be selected preopera-
tively if the diameter 4 mm. If the diameters are compa-
rable, the basilic vein is selected because of greater ease of
mobilization and the presence of fewer branches. Vein
diameter is measured at the mid-humerus and antecubital
region for both basilic and brachial veins.
Our surgical technique, which is similar to previous de-
scriptions of vein transpositions in the literature,5,7,23 is re-
viewed here (Fig 1). The preferred method of anesthesia is
either general or interscalene block. It is possible to perform
the procedure with conscious sedation and local anesthesia in
a compliant patient. The patient’s upper extremity is circum-
ferentially prepared to the axilla. A longitudinal incision is
begun superior and medial to the medial epicondyle of the
humerus. This can be placed directly over the brachial artery
pulse for a BrVT or more medially if a BVT is planned.
The vein of choice is identified; if vein size ismarginal, one
can look for a more suitable vein through this incision. The
median nerve and other cutaneous nerves are carefully identi-
fied and spared. The incision is then extended several centi-
meters at a time while sequentially freeing up the anterior
surface of the vein. The incision will usually extend all the way
to the axilla. Small side branches are ligated with silk ties and
clips; larger connections are oversewn with polypropylene
monofilament. Additional length can be gained bymobilizing
the vein below the antecubital crease if necessary.
The vein is then ligated distally, distended with hepa-
rinized saline with the anterior surface marked, and a Sera-
fin clamp is placed (Fig 2, A). A penetrating towel clamp is
used to temporarily approximate the skin edges, and the
vein is draped over the skin in the area of the planned
tunnel, which is then marked on the skin (Fig 2, B). A
tunneling device is brought subcutaneously, along the lat-eral aspect of the arm, distal to proximal. The vein is
carefully oriented and brought through the tunnel on a
gentle curve, reaching the brachial artery without tension.
The patient is systemically heparinized and the artery is
then mobilized for several centimeters. A standard end-to-
side vascular anastomosis is performed. The quality of the
thrill is then assessed. A pulsatile fistula may imply a kink or
twist in the vein, constriction from the tunnel, or outflow
obstruction. Radial and ulnar pulses are checked, and hep-
arin is reversed with protamine. A two-layer closure is
performed with running absorbable suture.
Most patients are discharged home the day of surgery
or the next day. All procedures were performed by one of
three attending physicians (W. C. S., B. H. T., S. R. M.)
with a resident or fellow (Fig 3).
Statistical analysis. The data are expressed as mean
standard deviation. Patient characteristics were compared
using the 2 test. Primary and primary-assisted patency
raters were evaluated using Kaplan-Meier plots and com-
pared using log-rank analysis. A value of P  .05 was
considered statistically significant. Statistical analysis was
performed using SAS 8.2 software (SAS Institute Inc, Cary,
NC).
RESULTS
The study comprised 38 men (64%) and 21 women
Fig 1. Anatomy of the upper arm during a basilic vein transposi-
tion. Alternatively, the brachial vein could be used as the conduit
and anastomosed to the brachial artery.(36%), and the median age was 55 years (range, 21-82
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of which 42 (71%) were BVTs, and 17 (29%) were BrVTs.
In 19 patients (32%), the transposition was the initial access
procedure (range, 0-3 prior procedures). The mean vein
size was 4.9  0.9 mm. The mean BVT diameter of 4.9 
1.0 mm and BrVT diameter of 5.0  0.8 mm were not
Fig 2. A,Dissection of the upper arm during a vein transposition.
B, The same patient, with the distal vein ligated just before the
subcutaneous tunnel.
Fig 3. A successful matured vein transposition seen in clinic.significantly different (P  .39).The median follow-up in our study was 8 months
(range, 0-64 months). The fistulas matured in 39 patients
(66%) and failed to mature in 12 patients. Three patients
were lost to follow-up before maturation could be assessed.
Five patients, two with BVT and three with BrVT, had
fistulas that were still awaiting maturation at 0 to 14 weeks
after the procedure. The maturation rate was 74% for BVT
(n  31) and 47% for BrVT (n  8). The difference
between the two groups was statistically significant (P 
.049). The mean time to maturation was 11.7 8.8 weeks
and was not significantly different between the two groups.
In 78% of patients (18 of 23) whose fistulas matured, vein
diameterswere larger than themean (4.9mm) comparedwith
50% (12 of 24) whose diameters were smaller than the mean.
This was statistically significant (P .043). The preoperative
vein diameter was not found in 12 patients.
Early primary functional patency rate at 6 months was
71% in BVTs and 40% in BrVTs. The 12-month functional
patency rate was 50% in BVTs and 40% in BrVTs (Fig 4),
which was not statistically significant (P  .115). Primary-
assisted patency rates (Fig 5) were virtually unchanged and
were also not significant (P  .154).
No preoperative characteristic, including age, sex, race,
vein size, number of previous accesses, presence of diabetes
mellitus, hypertension, hyperlipidemia, or smoking was
statistically different between the two groups (Fig 6), and
none of these factors affected maturation rates or patency
rates. The 30-day mortality rate was 0%, although one
patient was lost to follow-up immediately after the proce-
dure. Morbidity was 13%. Early complications included a
wound infection in two patients, hematoma in two patients
(one which required evacuation in the operating room),
and three cases of vascular steal syndrome, each requiring
subsequent distal revascularization and interval ligation
procedures. Each of these patients required a brachial
artery–to–brachial artery bypass. Three different conduits
were used: reversed saphenous vein, contralateral forearm
Fig 4. Primary functional patency. BVT, Basilic vein transposi-
tion; BrVT, brachial vein transposition.vein, and a 6-mm PTFE graft. Finally, one patient pre-
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that resolved without intervention.
Ten patients required 13 additional procedures, all of
whichwere percutaneous venous angioplasties. Six percutane-
ous interventions were performed in BVTs and seven in
BrVTs. Five patients had a successful result from the percuta-
neous intervention (3 BVTs and 2 BrVTs). However, five
required a subsequent operation to achieve dialysis access.
DISCUSSION
Radiocephalic or brachiocephalic arteriovenous fistulas
remain the initial dialysis access procedure of choice; how-
ever, very often patients do not have veins that are suitable
for creation of a fistula that will mature. Moreover, patients
who require long-term access over many years will un-
doubtedly require one or more procedures. Opinions differ
about which type of fistula is ideal for subsequent access.
Fig 5. Primary assisted patency. BVT, Basilic vein transposition;
BrVT, brachial vein transposition.
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Fig 6. Patient characteristics. HTN, Hypertension; HPL, hyper-
lipidemia.The basilic vein has been recognized as a suitable vein forcreating a native transposed fistula to the brachial artery.
Less attention has been given to the brachial vein as a
conduit for dialysis access.
At our institution, we will almost exclusively attempt an
autogenous fistula in a patient with suitable veins. Each
patient undergoes preoperative vein mapping in our vascu-
lar lab. If a suitable cephalic vein is not identified at the level
of the radial or brachial arteries, we then evaluate the
brachial and basilic veins. For many patients (68% in our
cohort), an upper extremity transposition is not the initial
access procedure. In appropriately selected patients, how-
ever, an upper extremity transposition may be a good first
access procedure, particularly if the forearm veins are small.
We will choose either the brachial or basilic vein for
transposition according to the better vein diameter. If vein
diameters are comparable, we select the basilic vein owing
to the greater ease of mobilization and fewer branches. It
has also now become our practice to take two measure-
ments of these veins, at both the mid-humerus and at the
antecubital region. Veins that are too small (4 mm) at
either region are usually excluded from usage.
Patients with large upper arm girth may not be suitable
candidates for a transposition because the longer tunnel
requires additional length of vein. Patients with prior upper
arm grafts or transpositions are poor candidates for a sub-
sequent BVT or BrVT because of tunneling issues and the
theoretic risk of increased arm edema. In patients with prior
upper arm vein transpositions, we do not perform addi-
tional ipsilateral transpositions; however, an arteriovenous
graft can be subsequently placed if needed.
Our experience with BrVT is, to our knowledge, the
largest reported review in the literature. We found that the
maturation rate was significantly better for BVTs (74%)
than BrVTs (47%); however, at 6 and 12 months, the
patency rates were not significantly different. These early
results are comparable with other centers.6-16 These data
indicate that most of our matured upper extremity trans-
positions remained functional for the duration of this study.
Despite these modest results, we believe that in carefully
selected patients, an upper extremity transposition is a good
autogenous access procedure. Another potential advantage
of vein transposition is that this procedure rarely precludes
a subsequent ipsilateral upper arm graft.
Our patency rates are somewhat less substantial com-
pared with recent and historical studies of PTFE
grafts.9,11,24-26 Cumulative patency rates in these retrospec-
tive studies were 46% to 75% at 1 year and beyond;
however, these same studies demonstrated a greater need
for secondary procedures to maintain graft patency com-
pared with our results. In addition, their patient popula-
tions tended to have a greater number of complications,
including graft infections, development of pseudoaneu-
rysms, and venous outflow stenoses.
The NKF-DOQI initiatives have attempted to promote
increased use of autogenous veins for fistulas. Autogenous
conduits have greater durability, increased patency, and re-
quire fewer procedures to maintain patency. Studies have also
shown that prosthetic grafts are more likely to become in-
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with a greater number of hospitalizations and increased cost.3
The addition of BrVT in our algorithm for hemodialy-
sis access was clearly related to the NFK-DOQI “push” for
greater autogenous accesses. A more difficult question to
answer is whether 1-year patency rates of 40% to 50% of
transposition arteriovenous fistulas are competitive enough
with results of prosthetic bridge grafts to routinely recom-
mend their preferential use. Because BrVT was limited to
17 patients, the role of this particular fistula in the hemo-
dialysis access algorithm is still uncertain. Longer follow-up
with a more robust sample size may further clarify the role
of BVT and BrVT.
CONCLUSION
Early results from this study demonstrate that BVT has
statistically greater maturation rates compared with BrVT;
however, BVT and BrVT are comparable with respect to early
primary functional patency and primary assisted patency rates.
Larger studies comparing the two fistula types with prosthetic
grafts are needed to evaluate their relative efficacy in the
dialysis population. Given the benefits of autogenous fistulas,
further investigations of this type will be beneficial.
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